Table 2 Comparison of patients infected with slow-growing or rapidly growing NTM
From: Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis
Patients with Slow-growing NTM (N = 17) | Patients with Rapidly Growing NTM (N = 8) | |||||
|---|---|---|---|---|---|---|
N | Median (range) | P-value | N | Median (range) | P-value | |
Body mass index in kg/m2 | 16 | 0.35 | 8 | 0.069 | ||
Before NTM infection | 19.8 (15.0–23.9) | 19.3 (14.7–21.7) | ||||
After NTM infection | 19.6 (15.2–25.9) | 20.4 (15.1–21.7) | ||||
FEV1 percent predicted | 17 | 0.11 | 7 | 0.23 | ||
Before NTM infection | 92 (53–115) | 84 (71–102) | ||||
After NTM infection | 91 (36–110) | 82 (48–91) | ||||
FEF25–75% predicted | 17 | 0.013 | 7 | 0.028 | ||
Before NTM infection | 79 (24–124) | 64 (42–123) | ||||
After NTM infection | 68 (13–110) | 51 (24–103) | ||||
IgE in kU/L | 16 | 0.55 | 7 | 0.61 | ||
Before NTM infection | 34 (8–2165) | 95 (18–419) | ||||
After NTM infection | 34 (9–1340) | 182 (57–429) | ||||
Vitamin A in μg/dL | 11 | 0.19 | 5 | 0.23 | ||
Before NTM infection | 39 (19–83) | 33 (15–45) | ||||
After NTM infection | 45 (25–79) | 30 (12–41) | ||||
Vitamin E in mg/L | 9 | 0.37 | 5 | 0.50 | ||
Before NTM infection | 8 (2–13) | 7 (6–11) | ||||
After NTM infection | 9 (2–14) | 5 (4–12) | ||||